Nutex Health Stock To $192?

Nutex Health (NUTX) stock has fallen 10.0% during the past day, and is currently trading at $148.19. Our multi-factor assessment suggests that it may be time to buy more shares of NUTX stock. We have, overall, a positive view of the stock, and a price of $192 may not be out of reach. We believe there is not much to fear in NUTX stock given its overall Strong operating performance and financial condition. Taken together with its Low valuation, this makes the stock look Attractive.

Below is our assessment:

Asset allocation is a smarter path than stock picking. The asset allocation strategies of Trefis’ Boston-based, wealth management partner yielded positive returns during the 2008-09 period when the S&P lost more than 40%. And now, Trefis High Quality Portfolio is part of it.

Let’s get into details of each of the assessed factors but before that, for quick background: With $993 Mil in market cap, Nutex Health provides healthcare through hospital and population health management divisions, operating 21 facilities across 8 states including micro-hospitals, specialty hospitals, and outpatient departments.

[1] Valuation Looks Low

This table highlights how NUTX is valued vs broader market. For more details see: NUTX Valuation Ratios

[2] Growth Is Very Strong

• Nutex Health has seen its top line grow at an average rate of 87.7% over the last 3 years
• Its revenues have grown 236% from $292 Mil to $981 Mil in the last 12 months
• Also, its quarterly revenues grew 239.9% to $268 Mil in the most recent quarter from $79 Mil a year ago.

This table highlights how NUTX is growing vs broader market. For more details see: NUTX Revenue Comparison

[3] Profitability Appears Strong

• NUTX last 12 month operating income was $359 Mil representing operating margin of 36.6%
• With cash flow margin of 18.1%, it generated nearly $178 Mil in operating cash flow over this period
• For the same period, NUTX generated nearly $121 Mil in net income, suggesting net margin of about 12.3%

This table highlights how NUTX profitability vs broader market. For more details see: NUTX Operating Income Comparison

[4] Financial Stability Looks Strong

• NUTX Debt was $359 Mil at the end of the most recent quarter, while its current Market Cap is $993 Mil. This implies Debt-to-Equity Ratio of 36.2%
• NUTX Cash (including cash equivalents) makes up $166 Mil of $965 Mil in total Assets. This yields a Cash-to-Assets Ratio of 17.2%

[5] Downturn Resilience Is Very Weak

NUTX has fared much worse than the S&P 500 index during various economic downturns. We assess this based on both (a) how much the stock fell and, (b) how quickly it recovered.

2022 Inflation Shock

• NUTX stock fell 99.6% from a high of $6,000.00 on 4 April 2022 to $26.25 on 18 December 2023 vs. a peak-to-trough decline of 25.4% for the S&P 500.
• The stock is yet to recover to its pre-Crisis high
• The highest the stock has reached since then is $190.49 on 11 December 2025 , and currently trades at $148.19

 
2020 Covid Pandemic

• NUTX stock fell 49.1% from a high of $412.50 on 17 March 2020 to $210.00 on 23 March 2020 vs. a peak-to-trough decline of 33.9% for the S&P 500.
• However, the stock fully recovered to its pre-Crisis peak by 4 April 2022

But the risk is not limited to major market crashes. Stocks fall even when markets are good – think events like earnings, business updates, outlook changes. Read NUTX Dip Buyer Analyses to see how the stock has recovered from sharp dips in the past.

The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.